Pioglitazone reduces systematic inflammation and improves mortality in apolipoprotein e knockout mice with sepsis

Intensive Care Medicine

Volumn 34, Issue 7, 2008, Pages 1304-1312

  Haraguchi, Go ^a   Kosuge, Hisanori ^a   Maejima, Yasuhiro ^a   Suzuki, Jun Ichi ^a   Imai, Takasuke ^a   Yoshida, Masayuki ^a   Isobe, Mitsuaki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Inflammation; Peroxisome proliferator activated receptor ; Sepsis

Indexed keywords

APOLIPOPROTEIN E; ENDOTOXIN; INTERLEUKIN 10; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; PIOGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ADHESION; CONTROLLED STUDY; ENZYME ACTIVITY; INFLAMMATION; MALE; MORTALITY; MOUSE; NONHUMAN; SEPSIS; SEPTIC SHOCK; SURVIVAL; VASCULAR ENDOTHELIUM;

ANIMALS; APOLIPOPROTEINS E; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HYPOGLYCEMIC AGENTS; INFLAMMATION; LIVER; LUNG; MALE; MICE; MICE, KNOCKOUT; PEROXIDASE; SEPSIS; THIAZOLIDINEDIONES;

EID: 46149100994     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-008-1024-9     Document Type: Article

References (36)

1. Vincent JL, Abraham E (2006) The last 100 years of sepsis. Am J Respir Crit Care Med 173:256-263
2. Yang H, Ochani M, Jianhua L, Qiang X, Tanovic M, Harris HE, Susarla SM, Ulloa L, Wang H, Diramio R, Czura CJ, Wang H, Roth J, Warren HS, Fink MP, Fenton MJ, Andersson U, Tracy KJ (2004) Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A 101:296-301
3. Merx MW, Liehn EA, Graf J, Sandt A, Schaltenbrand M, Schrader J, Hanrath P, Weber C (2005) Treatment after onset of sepsis in a murine model improves survival. Circulation 112:117-124
4. Yano K, Liaw PC, Mullington JM, Shih SC, Okada H, Bodyak N, Kang PM, Toltl L, Belikoff B, Buras J, Simms BT, Mizgerd JP, Carmeliet P, Karumanchi SA, Aird WC (2006) Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med 203:1447-1458
5. Temmesfeld-Wollbruck B, Brell B, David I, Dorenberg M, Adolphs J, Schmeck B, Suttorp N, Hippenstiel S (2007) Adrenomedullin reduces vascular hyperpermeability and improves survival in rat septic shock. Intensive Care Med 33:703-710
6. Babayigit H, Kucuk C, Sozuer E, Yazici C, Kose K, Akgun H (2005) Protective effects of β glucan on lung injury after cecal ligation and puncture in rats. Intensive Care Med 31:865-870
7. Murch O, Collin M, Hinds CJ, Thiemermann C (2007) Lipoproteins in inflammation and sepsis. I. Basic science. Intensive Care Med 33:13-24
8. Wendel M, Paul R, Heller AR (2007) Lipoproteins in inflammation and sepsis. II. Clinical aspects. Intensive Care Med 33:25-35
9. Ali K, Middleton M, Pure E, Rader DJ (2005) Apolipoprotein E suppresses the type II inflammatory response in vivo. Circ Res 97:922-927
10. Moretti EW, Morris RW, Podgoreanu M, Schwinn DA, Newman MF, Bennett E, Moulin VG, Mba UU, Laskowitz DT, for the Perioperative Genetics nd Safety Outcomes Study (PEGASYS) Investigative Team (2005) APOE polymorphism is associated with risk of severe sepsis in surgical patients. Crit Care Med 33:2521-2526
11. Bont N, Netea MG, Demacker PNM, Verschueren I, Kullberg BJ, Dijk KW, Meer JWM, Stalenhoef AFH (1999) Apolipoprotein E knock-out mice highly susceptible to endotoxinemia and Klebsiella pneumoniae infection. J Lipid Res 40:680-685
12. Oosten MV, Rensen PCN, Amersfoort ESV, Eck MV, Dam AMV, Breve JJP, Vogel T, Panet A, Berkel TJCV (2001) Apolipoprotein E protects against bacterial lipopolysaccharide-induced lethality. J Biol Chem 276:8820-8824
13. Kosuge H, Haraguchi G, Koga N, Maejima Y, Suzuki JI, Isobe M (2006) Pioglitazone prevents acute and chronic cardiac allograft rejection. Circulation 113:2613-2622
14. Shiojiri T, Wada K, Nakajima A, Katayama K, Shibuya A, Kudo C, Kadowaki T, Mayumi T, Yura Y, Kamisaki Y (2002) PPARγ ligands inhibit nitrotyrosine formation and inflammatory mediator expressions in adjuvant-induced rheumatoid arthritis mice. Eur J Pharmacol 448:231-238
15. Woerly G, Honda K, Loyens M, Papin JP, Auwerx J, Staels B, Capron M, Dombrowicz D (2003) Peroxisome proliferator-activated receptors α and γ down-regulate allergic inflammation and eosinophil activation. J Exp Med 198:411-421
16. Katayama K, Wada K, Nakajima A, Mizuguchi H, Hayakawa T, Nakagawa S, Kadowaki T, Nagai R, Kamisaki Y, Blumberg RS, Mayumi (2003) A novel PPARγ gene therapy to control inflammation associated with inflammatory bowel disease in a murine model. Gastroenterology 124:1315-1324
17. 2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways. J Immunol 171:6827-6837
18. Joner M, Farb A, Cheng Q, Finn AV, Acampado E, Burke AP, Skorija K, Creighton W, Kolodgie FD, Gold HK, Virmani R (2007) Pioglitazone inhibits in-stent restenosis in atherosclerotic rabbits by targeting transforming growth factor-beta and MCP-1. Arterioscler Thromb Vasc Biol 27:182-189
19. Frantz S, Hu K, Widder J, Bayer B, Witzel CC, Schmidt I, Galuppo P, Strotmann J, Ertl G, Bauersachs J (2004) Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction. Br J Pharmacol 141:9-14
20. Suzuki JI, Ogawa M, Futamatsu H, Kosuge H, Tanaka H, Isobe M (2006) A cyclooxygenase-2 inhibitor alters Th1/Th2 cytokine balance and suppresses autoimmune myocarditis in rats. J Mol Cell Cardiol 40:688-695
21. Onai Y, Suzuki JI, Kakuta T, Maejima Y, Haraguchi G, Fukasawa H, Muto S, Itai A, Isobe M (2004) Inhibition of IκB phosphorylation in cardiomyocyte attenuates myocardial ischemia/reperfusion injury. Cardiovasc Res 63:51-59
22. Yoshida M, Sawada T, Ishii H, Gerszten RE, Rosenzweig A, Gimbrone MA, Yasukochi Y, Numano F (2001) HMG-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro. Arterioscler Thromb Vasc Biol 21:1165-1171
23. Ogawa D, Nomiyama T, Nakamachi T, Heywood EB, Stone JF, Berger JP, Law RE, Bruemmer D (2006) Activation of peroxisome proliferator-activated receptorγ suppresses telomerase activity in vascular smooth muscle cells. Circ Res 98:e50-e59
24. Rittirsch D, Hoesel LM, Ward PA (2007) The disconnect between animal models of sepsis and human sepsis. J Leukoc Biol 81:137-143
25. Siddiqui AM, Cui X, Wu R, Dong W, Zhou M, Hu M, Simms H, Wang P (2006) The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferators-activated receptor-γ. Crit Care Med 34:1874-1882
26. Collin M, Abdelrahman M, Thiemermann C (2004) Endogenous ligands of PPAR-γ reduce the liver injury in haemorrhagic shock. Eur J Pharmacol 486:233-235
27. Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Patel NSA, Paola RD, Genovese T, Chatterjee PK, Fulia F, Cuzzocrea E, Rosa MD, Caputi AP, Thiemermann C (2004) Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-γ, reduces the development of nonseptic shock induced by zymosan in mice. Crit Care Med 32:457-466
28. 2 against the multiple organ failure caused by endotoxin. Crit Care Med 32:826-831
29. Paumelle R, Blanquart C, Briand O, Barbier O, Duhem C, Woerly G, Percevault F, Fruchart JC, Dombrowicz D, Glineur C, Staels B (2006) Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-α via inhibition of the protein kinase C signaling pathway. Circ Res 98:361-369
30. Wiel E, Lebuffe G, Robin E, Gasan G, Corseaux D, Tavernier B, Jude B, Bordet R, Vallet B (2005) Pretreatment with peroxisome proliferator-activated receptorα agonist fenofibrate protects endothelium in rabbit Escherichia coli endotoxin-induced shock. Intensive Care Med 31:1269-1279
31. Walley KR, Lukacs NW, Standiford TJ, Strieter RM, Kunkel SL (1996) Balance of inflammatory cytokines related to severity and mortality of murine sepsis. Infect Immun 64:4733-4738
32. Li Y, Li X, Haley M, Fitz Y, Gerstenberger E, Banks SM, Eichacker PQ, Cui X (2006) DTPA Fe (III) decreases cytokines and hypotension but worsens survival with Escherichia coli sepsis in rats. Intensive Care Med 32:1263-1270
33. Eyal FG, Hamm CR, Parker JC (2007) Reduction in alveolar macrophages attenuates acute ventilator lung injury in rats. Intensive Care Med 33:1212-1218
34. Campia U, Matuskey LA, Panza JA (2006) Peroxisome proliferator-activated receptor-γ activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors. Circulation 113:867-875
35. Marx N, Whorle J, Nusser T, Walcher D, Rinker A, Hombach V, Koenig W, Hoher M (2005) Pioglitazone reduces neointima volume after coronary stent implamtation. Circulation 112:2792-2798
36. Grainger DJ, Reckless J, McKilligin E (2004) Apolipoprotein E modulates clearance of apoptic bodies in vitro and in vivo, resulting in a systemic proinflammatory state in apolipoprotein E-deficient mice. J Immunol 173:6366-6375